WaveMan
WaveMan · Company
DFTX · Definium Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

DFTX Definium Therapeutics (DFTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001813814
Quote by TradingView
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
262
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $96.4K priced

What the filings say about DFTX

Insiders, 180 days
-$5.6M net sold
5 sellers · 55% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.0M
6 notices

Definium Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Definium Therapeutics, Inc. insiders sold a net $5.6M of stock across 14 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Roberts Brandi
Chief Financial Officer
SELL
2026-09-29 SECtraded 2026-09-25
3,377
$123.5K
-6.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 25, 2026.
  • The trade is 0.9% of the 394,528 shares held after it.
  • 4 other insiders sold within 30 days.
  • 262 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Roberts Brandi sold about $123.5K of DFTX under a 10b5-1 plan on Sep 25, 2026; 4 other insiders sold within 30 days and 262 funds added in the latest 13F quarter.
Sullivan Mark
Chief Legal Officer
SELL
2026-09-29 SECtraded 2026-09-25
14,051
$513.8K
-6.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 25, 2026.
  • The trade is 2.8% of the 494,228 shares held after it.
  • 4 other insiders sold within 30 days.
  • 262 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer Sullivan Mark sold about $513.8K of DFTX under a 10b5-1 plan on Sep 25, 2026; 4 other insiders sold within 30 days and 262 funds added in the latest 13F quarter.
Wiley Matthew T.
Chief Commercial Officer
SELL
2026-09-29 SECtraded 2026-09-25
3,097
$113.3K
-6.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 25, 2026.
  • The trade is 0.9% of the 359,036 shares held after it.
  • 4 other insiders sold within 30 days.
  • 262 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Wiley Matthew T. sold about $113.3K of DFTX under a 10b5-1 plan on Sep 25, 2026; 4 other insiders sold within 30 days and 262 funds added in the latest 13F quarter.
Barrow Robert
Chief Executive Officer
SELL
2026-09-29 SECtraded 2026-09-25
31,550
$1.2M
-6.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 3, 2026.
  • The trade is 1.4% of the 2,213,090 shares held after it.
  • 4 other insiders sold within 30 days.
  • 262 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Barrow Robert sold about $1.2M of DFTX under a 10b5-1 plan on Sep 25, 2026; 4 other insiders sold within 30 days and 262 funds added in the latest 13F quarter.
Karlin Daniel
Chief Medical Officer
SELL
2026-09-29 SECtraded 2026-09-25
10,853
$396.9K
-6.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 25, 2026.
  • The trade is 1.4% of the 792,846 shares held after it.
  • 4 other insiders sold within 30 days.
  • 262 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Karlin Daniel sold about $396.9K of DFTX under a 10b5-1 plan on Sep 25, 2026; 4 other insiders sold within 30 days and 262 funds added in the latest 13F quarter.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.6M over 180 days
-$3.0M over 90 days
below 80% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
262 funds bought in last quarter
more than 94% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.0% of the float short (float per yahoo 2026-10-26) · 4.9 days to cover · settled 2026-09-30
more than 66% of Pharma & Biotech
What changed in the last 30 days
Sep 29Chief Executive Officer Barrow Robert sold $1.2M under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 29Chief Legal Officer Sullivan Mark sold $513.8K under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 29Chief Medical Officer Karlin Daniel sold $396.9K under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 29Chief Financial Officer Roberts Brandi sold $123.5K under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 29Chief Commercial Officer Wiley Matthew T. sold $113.3K under a 10b5-1 plan (Sep 25)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch DFTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+187.0%12M
-14%+87%+188%+290%2025-102025-122026-022026-042026-062026-082026-10 2026-06-25 · Barrow Robert sold $1.3M2026-09-25 · Barrow Robert sold $1.2M2026-09-03 · Barrow Robert sold $721.7K2026-06-25 · Sullivan Mark sold $585.8K2026-09-25 · Sullivan Mark sold $513.8K2026-06-25 · Karlin Daniel sold $451.9K2026-03-25 · Barrow Robert sold $451.2K2026-09-25 · Karlin Daniel sold $396.9K2026-03-25 · Sullivan Mark sold $197.7K2026-03-25 · Karlin Daniel sold $148.1K2026-06-25 · Roberts Brandi sold $135.7K2026-06-25 · Wiley Matthew T. sold $129.1K2026-09-25 · Roberts Brandi sold $123.5K2026-09-25 · Wiley Matthew T. sold $113.3K2026-09-25 · ROBERT B BARROW filed to sell $1.2M2026-09-25 · DANIEL ROLLINGS KARLIN filed to sell $398.6K2026-09-25 · MATTHEW THOMAS WILEY filed to sell $113.8K2026-09-25 · BRANDI ROBERTS filed to sell $124.0K2026-09-25 · MARK SULLIVAN filed to sell $516.1K2026-09-03 · ROBERT B BARROW filed to sell $718.1K2026-06-25 · ROBERT B BARROW filed to sell $1.2M2026-06-25 · DANIEL ROLLINGS KARLIN filed to sell $422.8K2026-06-25 · BRANDI ROBERTS filed to sell $126.9K2026-06-25 · MATTHEW THOMAS WILEY filed to sell $120.8K2026-06-25 · MARK SULLIVAN filed to sell $548.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DFTX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
11,232,834 sh
$528.4M
Avoro Capital Advisors LLC
7,188,888 sh
$338.2M
Driehaus Capital Management LLC
6,845,276 sh
$322.0M
Jupiter Topco LLC
5,615,645 sh
$264.0M
Capital World Investors
5,367,723 sh
$252.5M

Congress trades in DFTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DFTX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ROBERT B BARROW
Filed 2026-09-25
$1.2M
DANIEL ROLLINGS KARLIN
Filed 2026-09-25
$398.6K
MATTHEW THOMAS WILEY
Filed 2026-09-25
$113.8K
BRANDI ROBERTS
Filed 2026-09-25
$124.0K
MARK SULLIVAN
Filed 2026-09-25
$516.1K

DFTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$5.7M position · as of 2026-06-30
12.9%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$13.2M position · as of 2026-06-30
3.1%
PROFUND VP PHARMACEUTICALS
$345.0K position · as of 2026-06-30
3.0%
Royce Smaller-Companies Growth Fund
$7.1M position · as of 2026-06-30
3.0%
Driehaus Micro Cap Growth Fund
$14.5M position · as of 2026-06-30
2.4%
Meridian Growth Fund
$12.0M position · as of 2026-06-30
2.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.6M sold by insiders over 180 days, 262 funds added last quarter, $3.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DFTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.04x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-4.61x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-64.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-51.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-38.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$4.2B
market value at close 2026-10-23 on 2026-07-30 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$166.3M-$103.9M-$93.9M-$66.3M
Net income-$183.8M-$108.7M-$95.7M-$56.8M
EPS (diluted)-2.06-1.54-2.44-1.84
Operating cash flow-$131.6M-$79.1M-$64.4M-$50.1M
Cash$257.8M$273.7M$99.7M$142.1M
Long-term debt$40.6M$21.9M$14.1Mn/a
SEC XBRL, fiscal years, as known on 2026-10-27

DFTX Stock Sonar score 5/7 axes

Find similar shapesCompare

DFTX ranks highest on institutional and government (94th percentile) and profitability (50th), and lowest on insider conviction (13th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
50
Inputs
  • Return on equity-64.1% · 46 pct, sector of 545
  • Return on assets-51.3% · 43 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-38.5% · 60 pct, sector of 576
Financial health
48
Inputs
  • Debt to equity0.04x · 64 pct, sector of 352
  • Cash flow to debt-4.61x · 31 pct, sector of 371
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.6M · 26 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
94
Inputs
  • Funds adding, latest quarter262 · 94 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
42
Inputs
  • Short interest, % of float+9.0% · 42 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DFTX filings, in plain words

Are Definium Therapeutics insiders buying or selling DFTX?

In the 180 days to 2026-10-27, Definium Therapeutics insiders were net sellers, a net $5.6M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of DFTX?

Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $3.0M of stock; the latest, by ROBERT B BARROW, was filed 2026-09-25.

Read the full summary

In the 180 days to 2026-10-27, Definium Therapeutics insiders were net sellers of DFTX, a net $5.6M across purchases and sales reported on Form 4 by 5 sellers. 55% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $3.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies